Proffitt & Goodson’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Proffitt & Goodson’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.8K	Hold	43	–	–	﹤0.01%	263
2026 Q1	$5.49K	Hold	43	–	–	﹤0.01%	253
2025 Q4	$5.24K	Sell	43 -47	-52%	-$5.39K	﹤0.01%	258
2025 Q3	$9.02K	Hold	90	–	–	﹤0.01%	261
2025 Q2	$7.46K	Hold	90	–	–	﹤0.01%	215
2025 Q1	$7.3K	Hold	90	–	–	﹤0.01%	211
2024 Q4	$8.11K	Hold	90	–	–	﹤0.01%	205
2024 Q3	$8.89K	Hold	90	–	–	﹤0.01%	218
2024 Q2	$8.34K	Hold	90	–	–	﹤0.01%	230
2024 Q1	$8.54K	Hold	90	–	–	﹤0.01%	197
2023 Q4	$8.04K	Hold	90	–	–	﹤0.01%	190
2023 Q3	$6.57K	Hold	90	–	–	﹤0.01%	198
2023 Q2	$7.49K	Hold	90	–	–	﹤0.01%	192
2023 Q1	$6.86K	Hold	90	–	–	﹤0.01%	200
2022 Q4	$7.47K	Hold	90	–	–	﹤0.01%	201
2022 Q3	$7K	Hold	90	–	–	﹤0.01%	211
2022 Q2	$7K	Hold	90	–	–	﹤0.01%	221
2022 Q1	$8K	Buy	+90	New	+$8.31K	﹤0.01%	235
2016 Q1	–	Sell	-17,015	Closed	-$1.19M	–	45
2015 Q4	$1.19M	Sell	17,015 -595	-3%	-$40.6K	0.7%	22
2015 Q3	$1.1M	Sell	17,610 -3,855	-18%	-$304K	0.69%	25
2015 Q2	$1.8M	Sell	21,465 -1,425	-6%	-$111K	1.05%	10
2015 Q1	$1.72M	Sell	22,890 -2,076	-8%	-$145K	1%	10
2014 Q4	$1.55M	Sell	24,966 -1,572	-6%	-$89.6K	0.92%	12
2014 Q3	$1.38M	Sell	26,538 -690	-3%	-$35.2K	0.85%	15
2014 Q2	$1.4M	Buy	27,228 +45	+0.2%	+$2.03K	0.84%	17
2014 Q1	$1.29M	Sell	27,183 -876	-3%	-$44.8K	0.83%	21
2013 Q4	$1.22M	Buy	28,059 +606	+2%	+$25.1K	0.79%	23
2013 Q3	$1.18M	Sell	27,453 -1,935	-7%	-$78.4K	0.85%	16
2013 Q2	$1.02M	Buy	+29,388	New	+$1.03M	0.79%	26

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Proffitt & Goodson's XBI Position: Q2 2026 in Review

Proffitt & Goodson held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 43 shares worth $6.8K. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Proffitt & Goodson first reported a position in XBI in Q2 2013 and has held it in 29 quarters since. The position peaked at $1.8M in Q2 2015. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Proffitt & Goodson held 43 shares of State Street SPDR S&P Biotech ETF worth $6.8K as of Q2 2026.
Proffitt & Goodson left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Proffitt & Goodson's portfolio in Q2 2026, its #263 holding.
Proffitt & Goodson first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 29 quarters since.
Proffitt & Goodson's State Street SPDR S&P Biotech ETF position peaked at $1.8M in Q2 2015.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Proffitt & Goodson's 13F filing for Q2 2026, filed 22 Jul 2026.